Pada pengobatan Tuberkulosis Resistan Obat (TB RO), ada kemungkinan pasien mengalami Kejadian Tidak Diinginkan (KTD). KTD serius dapat menyebabkan kematian, keadaan yang mengancam yang jiwa, kecacatan permanen, dan memerlukan perawatan di rumah sakit. Maka dari itu, setiap fasilitas kesehatan TB RO perlu mencatat dan melaporkan KTD Serius. Tujuan dari tugas khusus ini adalah untuk mencatat dan menganalisis KTD Serius pada pasien TB RO di Rumah Sakit Universitas Indonesia pada periode Juli – November 2022. KTD Serius pada pasien TB RO dilihat dari Catatan Perkembangan Pasien Terintegrasi (CPPT) pada sistem AFYA Rumah Sakit Universitas Indonesia. Kemudian KTD serius dicatat ke dalam Formulir Pelaporan KTD Serius dan dianalisis. Hasil menunjukkan bahwa ditemukan 8 pasien TB RO yang mengalami KTD serius dan 3 pasien diantaranya mengalami KTD serius sebanyak 2 kali sehingga total ada 11 laporan KTD serius. KTD serius yang ditemukan pada pasien antara lain sesak napas (72,7%), mual muntah (36,4%), nyeri (36,4%), gangguan pencernaan (18,2%), demam (18,2%), batuk darah (9%), dan ruam gatal (9%). Kesimpulannya adalah terdapat sebanyak 11 laporan KTD serius pada pasien TB RO dan KTD serius yang paling banyak ditemukan pada pasien adalah sesak napas.

---

In the treatment of drug-resistant Tuberculosis (DR TB), there is a possibility that the patient will experience an adverse event. Serious adverse events can cause death, life-threatening conditions, permanent disability, and hospitalization. Therefore, every DR TB health facility needs to record and report serious adverse events. The purpose of this special assignment was to record and analyze serious adverse events in DR TB patients at the Universitas Indonesia Hospital in the period July – November 2022. Serious adverse events in DR TB patients can be seen from the integrated patient progress record in the Universitas Indonesia Hospital AFYA system. Then the serious adverse event was recorded on the serious adverse event reporting form and analyzed. The results showed that there were 8 DR TB patients who had serious adverse events, and 3 of them had two serious adverse events, for a total of 11 serious adverse events reported. Serious adverse events found in patients included shortness of breath (72.7%), nausea, vomiting (36.4%), pain (36.4%), digestive disorders (18.2%), fever (18.2%), coughing up blood (9%), and an itchy rash (9%). In conclusion, there were 11 reports of serious adverse events in DR TB patients, and the most common serious adverse event found in patients was shortness of breath.